Senzime receives TetraSens single-use electrode order from South Korea at a value of more than 1 Million SEK

Press release: Uppsala, December 22, 2020. Senzime AB (publ) today announces that they have received an additional order of TetraSens single-use electrodes from their distributor in South Korea. The order value amounts to more than 1 Million SEK and delivery will take place during December.


This is the sixth larger order placed by Senzimes distributor in South Korea since their market launch in August 2019. There are more than 3,000 hospitals in South Korea and more than 700 000 operations are performed annually where anesthesia and muscle relaxants are used. The company also expects that South Korea's state reimbursement system will include this type of disposable sensors in 2021, an update on this will be sent out when officially confirmed.

Pia Renaudin, CEO of Senzime states, "As we deliver more and more systems to our customers the TetraSens disposable electrode will constitute a larger part of our recurrent revenue as described in our business model”

TetraGraph is a unique digital system that measures the presence and depth of neuromuscular blockade to enable the doctor to determine the correct drug dosage and assess when the patient is ready to breathe on their own without the risk of complications. In addition to South Korea, Senzime has launched sales of TetraGraph in Japan, Australia, Europe and the United States.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                   

Tel: +46 (0)70-813 34 17, email:   


About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, is Certified Adviser for Senzime.

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on December 22, 2020, 11:00.

Explore our patient monitoring solutions

Get product details

How can Senzime’s products help to eliminate in-hospital complications?
Contact us to discuss your needs or schedule a product demo.